Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine
EMA Explains Its ‘Softly Softly’ Approach
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
